ArticleLeukemia & lymphoma2016

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Mark H Kirschbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.